NCT02381496View on ClinicalTrials.gov

A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Healthy
Interventions
DRUG

ACT-453859 1 mg

Capsule

DRUG

ACT-453859 3 mg

Capsule

DRUG

ACT-453859 10 mg

Capsule

DRUG

ACT-453859 30mg

Capsule

DRUG

ACT-453859 100 mg

Capsule

DRUG

ACT-453859 300 mg

Capsule

DRUG

ACT-453859 800 mg

Capsule

OTHER

Placebo

Matching ACT-453859 placebo capsule

DRUG

Setipiprant 500 mg

Capsule

DRUG

Setipiprant 1000 mg

Capsule

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT02381496 - A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968) | Biotech Hunter | Biotech Hunter